Graphene Frontiers Presentation - IEEE

Report
http://graphenefrontiers.com
Confidential and Proprietary
Biosensors: $21B
Medical biosensors play a major role in improving patients' quality of life.
Global Medical Biosensors market forecasted to grow at CAGR 10.16% 2013-2018
Problem
1st Gen POC Diagnostics: Not Good Enough
• Limited Sensitivity
• Slow
• Inaccurate
Next Gen POC Diagnostics: Quantum Leap
Confidential and Proprietary
Graphene Field Effect Transistor (GFET) chips
and Reader Device
Devices: GFET
GFET = Graphene Field Effect Transistor
Confidential and Proprietary
Nobel Prize in Physics 2010
Confidential and Proprietary
GF SIX BIOSENSOR PLATFORM
ELISA
GFET
Limit of Detection (LOD)
1-20pg/ml
100x-1000x better
than ELISA
Ability to Multiplex
No (1 antibody per run)
Yes
Speed
May take hours for
incubation and processing
Sample to results in minutes
Cost
Expensive Optical Readers
All electronic, lower cost
Ease of Use
Trained Lab Tech Needed
After sample obtained,
the rest is automated
Specificity of detection
Relies on secondary
detection antibody
Higher false positives
Specific and direct
detection – all electronic
Graphene Frontiers Biosensors and IoT
GF Biosensors will transform healthcare and
enable:
• Healthcare technology growth
• Healthcare connectivity
• Epidemiology studies at national level
• Big Data analytics
Graphene Frontiers Biosensors and IoT
GF Biosensors will enable: (continued)
• Connection to CDC and generate alerts when
infectious diseases arise in certain areas
• Easy and affordable diagnostics in rural areas
• Connection between small clinics and large
medical centers to treat difficult diseases
Mike Patterson, CEO
[email protected]
Victoria Tsai, SVP Business Development and Tech R&D
[email protected]
http://graphenefrontiers.com
Confidential and Proprietary

similar documents